Sjögren's Disease
Also known as: Sjögren's syndrome
Methodology & AI Transparency ⓘ
Sjögren's Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Sjögren's disease? Sjögren's disease, previously called Sjögren's syndrome, is a chronic (long-lasting) autoimmune disease .
- 2 Real-world patient consensus: Diagnostic registry M34.3: Sjögren's Disease is managed within Autoimmune Disease (aka Sjögren's syndrome).
- 3 Typical cash cost range: Primary evaluation for Sjögren's Disease incorporates autoantibody serology panels in Sjögren's Disease (M34.3: (ANA) and symptom diary review.
- 4 Top reported side effects / signs: Key Autoimmune Disease biomarkers for Sjögren's Disease (M34.3): ANA, RF, Anti-CCP in Sjögren's Disease (M34.3: & Complement C3/C4) & CBC, ALT & in Sjögren's Disease (M34.3: Creatinine (DMARD safety)) (Within normal safety monitoring limits (M34.3)).
Ask our AI Specialists anything about Sjögren's Disease
What Is Sjögren's Disease?
What is Sjögren's disease? Sjögren's disease, previously called Sjögren's syndrome, is a chronic (long-lasting) autoimmune disease . When you have an autoimmune disease, your immune system attacks healthy tissues and organs by mistake. In Sjögren's disease, your immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. This causes a dry mouth and dry eyes . You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjögren's disease can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Sjögren's Disease (M34.3, Autoimmune Disease) reflects pro-inflammatory cytokine cascades in Sjögren's Disease (M34.3: (TNF-alpha). Cross-referenced with NIH MeSH (Sjogren's Syndrome), longitudinal control is benchmarked via ANA, RF, Anti-CCP in Sjögren's Disease (M34.3: & Complement C3/C4).
Common Symptoms & Clinical Signs
- • Dry eyes. Your eyes may burn or itch or feel like they have sand in them. Sometimes your vision may be blurry, or bright lights may bother you
- • Dry mouth. Your tongue and your throat may feel dry. You might have trouble swallowing , speaking , and tasting
- • Presentation of Sjögren's Disease (M34.3): symmetric swelling and in Sjögren's Disease (M34.3: warmth in small)
- • Secondary Sjögren's Disease clinical sign: systemic inflammatory fatigue, in Sjögren's Disease (M34.3: low-grade fevers, dry)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sjögren's Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M34.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Rheumatoid Arthritis, Lupus & Autoimmune | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ANA, RF, Anti-CCP in Sjögren's Disease (M34.3: & Complement C3/C4) | Disease-activity remission targets (M34.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, ALT & in Sjögren's Disease (M34.3: Creatinine (DMARD safety)) | Within normal safety monitoring limits (M34.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & ESR [Sjögren's Disease M34.3] | hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M34.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sjögren's Disease
Treatment selection for Sjögren's Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sjögren's Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that. Rheumatology international • 2021-09-15 • Phase III Randomized Trial | N = 32 | 88/100 | PMID 34165604 ↗ |
| Can This Approach Help? Inside the Latest Research on Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus BICLA and SRI4 may be discordant in SLE trials. Lupus science & medicine • 2025-05-19 • Phase III Randomized Trial | N = 87 | 88/100 | PMID 40389370 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term effectiveness of a novel intra-oral electro-stimulator for the LEONIDAS-1 results support progression to a phase III definitive randomised controlled trial of salivary electrostimulation in individuals with Sjogren's syndrome. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology • 2023-08-15 • Phase III Randomized Trial | N = 15 | 88/100 | PMID 37220073 ↗ |
Sjögren's Disease Patient Community & “People Like Me” Threads
Filter Sjögren's Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.